Kalaris Therapeutics Inc (KLRS) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Currency In USD
| Previous Close | 1.35 |
| Open | 1.31 |
| Day High | 1.37 |
| Day Low | 1.26 |
| 52-Week High | 11.88 |
| 52-Week Low | 1.25 |
| Volume | 37,986 |
| Average Volume | 77,371 |
| Market Cap | 30.47M |
| PE | -0.63 |
| EPS | -2.02 |
| Moving Average 50 Days | 2.33 |
| Moving Average 200 Days | 4.84 |
| Change | -0.07 |
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting
GlobeNewswire Inc.
Jan 28, 2026 9:05 PM GMT
BERKELEY HEIGHTS, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company developing differentiated therapies for retinal diseases, today announced that clinical data
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
GlobeNewswire Inc.
Dec 17, 2025 10:59 PM GMT
BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (NASDAQ: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal disea
Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD
GlobeNewswire Inc.
Dec 17, 2025 9:01 PM GMT
TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a single injection TH103 was generally well tolerated, supporting further dose escalation beyond 2.5 mg TH103 showed a 27 to 51-fold lower